Comparing the effectiveness between the use of atorvastatin and rivaroxaban for deep vein thrombosis prophylaxis, inflammatory responses, and coagulation activities in cancer patients who have a high risk of thrombosis while undergoing chemotherapy: focus on IL-6, CRP, TF, F1+2, D-dimer, NF-kB, and TNF-alpha serum level and Doppler ultrasonography

Dr. Kariadi Hospital0 个研究点目标入组 86 人开始时间: 2020年12月17日最近更新: 2023年5月22日

适应症

试验速览

2022 Preprint results in https://doi.org/10.21203/rs.3.rs-2177111/v1 (added 27/10/2022) 2023 Results article in https://doi.org/10.1186/s12959-023-00497-0 (added 09/05/2023)

•1. Cancer patient with a definite diagnosis of cancer based on anatomy pathological examination
•2. Cancer patients who have not received any chemotherapy
•3. Khorana risk score =2
•4. Age 18-60 years old
•5. Has signed the participant agreement

•1. Deep vein thrombosis diagnosed with Doppler ultrasonography examination at baseline
•2. Within 14 days post-surgery
•3. Pregnancy
•4. Taking an anti-thrombotic drug
•5. Congenital altered coagulation system
•6. Creatinine clearance <30 ml/minute
•7. Patients with AST level >3x upper normal limit
•8. Patients with total bilirubin total >5 mg/dl
•9. Patients with CK >3 x upper normal limit
•10. Performance status ECOC =3
•11. Patients with cardio-cerebrovascular disease
•12. Patients with infection
•13. Patients with active, major, serious, life-threatening bleeding that can not be overcome with medical or surgical intervention, esp in a critical area (intra-cranial, pericardial, retroperitoneal, intra-occular, intra-artikular, intraspinal)
•14. Malignant hypertension
•15. Congenital coagulopathy or severe platelet dysfunction
•16. Severe and persistent thrombocytopenia (<20,000/µl)

发起方

Dr. Kariadi Hospital